Source link : https://www.newshealth.biz/health-news/two-soliris-biosimilar-approved-for-pnh-in-the-united-states/
The US Food and Drug Administration (FDA) recently approved two biosimilars to Soliris for the treatment of two rare diseases — paroxysmal nocturnal hemoglobinuria (PNH), a debilitating and potentially deadly blood disorder, and atypical hemolytic uremic syndrome. The first, Bkemv (eculizumab-aeeb, Amgen), was approved in May, and the second, Epysqli (eculizumab-aagh, Samsung Bioepis), was approved […]
Author : News Health
Publish date : 2024-07-24 06:59:29
Copyright for syndicated content belongs to the linked Source.
Categories